CinnoRA®

Adalimumab

Physioject™ 40mg/ 0.8ml

CERTIFIED EU GMP

CinnaGen

Orchid Pharmed

Sky's the Limit

has it all...

LANZO®

Lansoprazole

Abidi

- ✓ Highest number of FDA approved indications[1]
- ✓ High efficacy and rapid acid-related symptoms relief[2]
- ✓ Long duration of action[2]
- ✓ As safe as placebo[3]
- ✓ Very low drug interactions[3]
- ✓ No interaction with Clopidogrel based on FDA label 2012[3]
- ✓ Class B in pregnancy[1]

References:
1. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer Health, Inc; 2011. p 1975.
2. Am J Gastroenterol 2001; 96: 3089-3098.
3. Drug Safety 2006; 29: 769-784.

Ezonium®

Esomeprazole

Abidi

- **Fast and long-lasting acid control** [1]
- **The best choice in GERD and EE management** [1,2]
- **Proven efficacy in resistant patients with GERD and EE** [2]

References:
1. Am J Gastroenterol 2003; 98: 2616-2620.
2. Clin Drug Invest 2009; 29 (12): 803-810.

abidi
Gastroenterology

ASACOL® COMBINED Abbreviated Prescribing Information. Presentations: Tablets: Coated, red-brown, oblong gastro-resistant tablets containing 400mg or 800mg mesalazine. Suppository: Light grey-brown, torpedo-shaped suppositories containing 500mg mesalazine. Enema: Brownish suspension containing mesalazine 2g in 50mL or 4g in 100mL. **Indications:** Tablets: Induction and maintenance of remission of mild to moderate ulcerative colitis (UC), maintenance of remission of Crohn's ileo-colitis in adults and children (age 6-18 years). Suppository: Induction of remission of mild to moderate proctitis and proctosigmoiditis and maintenance of remission of mild to moderate proctitis in adults. Enema: Induction and maintenance of remission of proctitis, proctosigmoiditis and left-sided colitis in adults. **Pharmacokinetics:** Asacol® gastro-resistant tablets release mesalazine at a pH above 7 e.g. within the terminal ileum and the colon. Asacol® tablets have been designed to be poorly absorbed in the digestive tract. The majority of the administered dose remains in the gut lumen and mucosal tissue. Mesalazine is metabolised both by the intestinal mucosa and the liver to the inactive metabolite N-acetyl mesalazine. The elimination of mesalazine is essentially urinary and faecal in the form of mesalazine and its N-acetyl metabolite. **Dosage and administration:** Tablets: The tablets must be swallowed whole and not chewed, crushed or broken. *Adults: Induction of remission of UC*: 2.4g once daily or in divided doses up to 4.8g mesalazine daily in divided doses. *Maintenance of remission of UC*: 1.6g – 2.4g mesalazine a day taken once daily or in divided doses. *Maintenance or remission of Crohn's ileo-colitis*: 2.4g mesalazine daily in divided doses. *Children 6 years of age and older: Induction of remission*: To be determined individually, starting with 30-50 mg/kg/day in divided doses. Maximum dose: 75 mg/kg/day in divided doses. The total dose should not exceed 4.0 g/day. *Maintenance of remission*: To be determined individually, starting with 15-30 mg/kg/day in divided doses. The total dose should not exceed 2.0 g/day. It is generally recommended that half the adult dose may be given to children up to a body weight of 40 kg; and the normal adult dose to those above 40 kg. Suppository: *Induction of remission*: 1 suppository (500mg mesalazine) 3 times daily after defecation. *Maintenance of remission*: 1 suppository (500mg mesalazine) twice daily after defecation. Enema: *Induction and maintenance of remission*: One enema (2g or 4g mesalazine) administered at night after defecation daily. **Contraindications:** Patients with known hypersensitivity to salicylates or mesalazine, severe liver or renal impairment (GFR < 30 mL/min/1.73 m²). **Precautions:** Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment and then every 4 weeks for the following 12 weeks. If the findings are normal, follow-up tests should be carried out every three months. If additional symptoms occur, these tests should be performed immediately. Asacol® is not recommended for use in patients with renal impairment. Patients with galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Caution should be exercised in patients with: raised serum creatinine, proteinuria, liver impairment, gastric or duodenal ulcers, previous myo- or pericarditis of allergic background regardless of its origin, pulmonary disease, in particular asthma in the elderly. In case of previous mesalazine-induced cardiac hypersensitivity Asacol® must not be reintroduced. Treatment must be stopped immediately and patients must seek immediate medical attention in case of acute symptoms of intolerance such as cramps, abdominal pain, fever, severe headache or rash or if blood dyscrasia is suspected. In patients with a history of sensitivity to sulphasalazine, therapy should be initiated only under close medical supervision. There is only limited documentation for an effect in children (age 6-18 years). **Pregnancy and lactation:** There are no adequate data on the use of Asacol® in pregnant women. However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on pregnancy or on the health of the fetus/newborn child. N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. The clinical significance of this has not been determined. Asacol® should only be used during pregnancy or breast-feeding if the potential benefit outweighs the possible risk. **Interactions:** Mesalazine can increase the myelosupressive effects of azathioprine, or 6-mercaptopurine or thioguanine. Haematological parameters, especially the leucocyte, thrombocyte, and lymphocyte cell counts should be monitored regularly (weekly), especially at initiation of such combination therapy. If white blood cells are stable after 1 month, testing every 4 weeks for the following 12 weeks followed by 3 monthly monitoring intervals appears to be justified. There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin. **Adverse reactions:** *Common**: Dyspepsia and rash. *Uncommon**: Eosinophilia, paresthesia, urticaria, pruritus, pyrexia and chest pain. *Rare*: Headache, dizziness, myocarditis, pericarditis, photosensitivity, abdominal pain, diarrhoea, flatulence, nausea and vomiting. *Very rare*: Altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia), hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis, peripheral neuropathy, allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis), interstitial pneumonia*, eosinophilic pneumonia*, lung disorder*, acute pancreatitis, changes in liver function parameters (increase in transaminases and cholestasis parameters), hepatitis, cholestatic hepatitis, alopecia, myalgia, arthralgia, impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency, nephrotic syndrome*, renal failure which may be reversible on early withdrawal* and oligospermia (reversible). **Licence holder and supplier:** Tillotts Pharma AG, Switzerland.
* Only for Asacol® Tablets formulation.

This abbreviated prescribing information is based on the Products' Company Core Data Sheets (last update October 2017). Trade name, formulations, pack sizes, indications and dosages may vary from country to country. Before prescribing, please consult your local Summary of Product Characteristics. Detailed prescribing information is available from all suppliers of Asacol® and Tillotts Pharma AG, Switzerland (www.tillotts.com). **The trademark Asacol is registered in over 55 countries as Asacol® and as Octasa™, Fivasa™, Lixacol™, Asacolon™ in the United Kingdom, France, Spain and Ireland, respectively. The rights to Asacol, including the rights to the trademark, are owned by Tillotts Pharma AG in various countries except for the following: Switzerland, USA, United Kingdom, Canada, Italy, Belgium, the Netherlands and Luxembourg.**

(1) Sandborn et al., Gastroenterology 2010;138:1286–1296. (v 1.0) p.1. The Asacol™ reference in this study relates to Allergan's Asacol™, to which Tillotts Pharma's Asacol™ 400mg is functionally equivalent. Allergan and its affiliates market their mesalazine products under the trademark Asacol™ in the USA, Canada and the United Kingdom. Tillotts Pharma markets its mesalazine products under the trademark Asacol™ in over 55 countries throughout continental Europe and the rest of the world. Allergan and Tillotts Pharma are not related companies.
(2) Timeus S. And Marchi P. Poster P492, 12th European Crohn's Colitis Organization (ECCO) Congress, Barcelona, Spain, Feb 15.18, 2017.

ZERIA GROUP
TILLOTTS PHARMA
GI-health is our passion™

www.tillotts.com

PM-ALL-00040_V1.1

ACTOVERCO
Together for a healthy future
Internal Medicine Department

No. 58, 8th St., Kooye Nasr (Gisha St.), Tehran, IR Iran, Postal Code: 1446863914, Telefax: +98 (21) 416 370 00
ACT.MKT.INT.07.1398.0618
www.actoverco.com

Boston Scientific
Advancing science for life™

FUJIFILM
Value from Innovation

Medtronic

CANTEL

Mauna Kea
Technologies

restech
Reflux Diagnosed

نشانی: تهران، خیابان شریعتی، بالاتر از میرداماد، خیابان شواری، پلاک ۴۲

۲۶۷۰۰۵۰۱

www.m-f-agroup.com

PENTAX
MEDICAL

EXCELLENCE IN FOCUS

DEFINA [EPK- 3000]
HD Processor with 1500w xenon lamp

IMAGINA [EPK-i5500c]
Innovative FULL HD Technology (LED & cmos)

EPK-i5000 [Xenon + CCD]
FULL HD processor

Broaden your perspective
Explore the EUS-J10 Line-up

The new way of doing
The new way of seeing
The new way of treating

- زاویه اسکن 150 درجه – میدان دید از 3 mm
- جدید ترین تکنولوژی کریستالهای اولتراسوند
- فرکانس پیوسته 5-13 MHZ جهت ایجاد بهترین تصاویر اولتراسوند با دامنه نفوذ استثنایی
- کانال کار ویژه mm4.0 (unique enlarged working channel) جهت انجام پروسه درمانی interventional با بهترین قابلیت کنترل

FIBROTOUCH®

medwork. Intelligent Endoscopy FIBROTOUCH

GAOTOTEC PENTAX MEDICAL Strong Biotech Corporation

شرکت مهندسی طب داخلی پیشرو

بلوار میر داماد، نبش مصدق شمالی، شماره ۲۲۱
تلفن:۵-۲۱ ۲۲ ۲۵ ۵۴
۷۲۸ ۸۳۰ ۰۰
فاکس:۴۷ ۲۵ ۸۵ ۲۲

Mesatin®

Mesalazine ER 500 mg

A Trust Toward Healing

Tasnim Pharmaceutical Co.

- اولین کپسول مزالازین تولید داخل با آزادسازی کنترل شده در روده
- **An aminosalicylate anti-inflammatory drug (5-ASA), used to treat inflammatory bowel disease (IBD), management of UC & CD**
- **Capsule Extended Release 500mg**

PENTASA®
MESALAZINE

Unique Microgranules ...

5-ASA releases gradually[1]...



... Provide sufficient 5-ASA for the whole colon[3]

Optimal for UC patients

General API of Pentasa/ With Crohn's Disease PENTASA® Composition: Mesalazine (5-ASA) available as compressed microgranules (slow release) 500 mg or 1g tablets, 1g sachets, 2g sachets (Xtend), 1g enema, 1g suppositories. Indications: 500mg and 1g tablets: acute treatment of ulcerative colitis (inflammation of the large intestine with ulceration) and prophylaxis for relapse, and treatment for symptomatic improvement in cases of active Crohn's disease. 1g sachets and 2g sachets (Xtend): mild to moderate ulcerative colitis and to help maintain freedom from further attacks, and crohn's disease (active disease and maintenance treatment). 1g enema: acute episode of distal or left-sided ulcerative colitis. 1g suppositories: treatment of ulcerative colitis limited to rectum. Dosage and Administration: Oral formulations: Adults: Acute treatment of ulcerative colitis: up to 4g Pentasa/day (divided into doses per day or once daily). Maintenance dose: in terms of tablet formulations (1.5 g mesalazine/day, 3 times a day) or up to 2g mesalazine/day in case of the sachet formulations. Crohn's disease: Acute therapy: Up to 4g mesalazine daily in divided doses. Children from the age of 6 years: Acute therapy for both ulcerative colitis and Crohn's disease: It is usually recommended that children with a body weight of up to 40 kg should receive half the dose given to adults and children above 40 kg should receive the normal adult dose. As with adults, half of this dose should be used for maintenance prophylaxis. For the sachet formulations, the granules must not be chewed. The contents of the sachet should be emptied onto the tongue and washed down with some water or orange juice. 1g Suppositories: One suppository, one time daily for 2-4 weeks. 1g Enema: One enema at bedtime. Warnings and precautions Talk to your doctor or pharmacist before taking PENTASA: If you are allergic to sulphasalazine (risk of allergy to salicylates), if you currently have or have previously had liver and/or kidney disease, if you have a medical condition that can make you prone to bleeding, if you have an active peptic ulcer (stomach ulcer or duodenal ulcer), if you are on medication that may affect kidney function e.g. non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid, if you have lung problems in particular asthma, if you suddenly develop abdominal cramps, abdominal pain, fever, severe headache and rash. In such circumstances, you should stop taking PENTASA® immediately. While you are on treatment with this medicine, your doctor will normally arrange blood tests to check your kidney function especially at the beginning of treatment. Contraindications: If you are allergic (hypersensitive) to mesalazine or any of the other ingredients of this medicine, if you are allergic to other salicylates e.g. acetylsalicylic acid, if you have severe liver and/ or kidney problems. Pregnancy and lactation: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. There is limited experience with the use of mesalazine during pregnancy and breast-feeding. Blood disorders have been reported in new-borns of mothers being treated with this medicine. The newborn may develop allergic reactions after breast-feeding, e.g. diarrhoea. If the newborn develops diarrhoea, breast-feeding should be discontinued. Side effects: Common side effects are: Diarrhea, abdominal pain, nausea, vomiting, headache, rash, flatulence (passing wind), and dizziness (with Pentasa 500mg tablets, 1g enema, 1g suppositories). Following rectal administration local reactions such as pruritus, rectal discomfort and urge may occur. Storage: Store at room temperature.

G-Pe-AM-Oct-182227

1. Clemett D et al Drugs 2000 Apr; 95 (4): 929 – 956
2. Layer PH et al. Gastroenterology 1995; 108:1427-1433
3. Wilding IR, et al. Practical Gastroenterology 1999; 1:392-397z

FERRING PHARMACEUTICALS
Middle East, Turkey & Africa
E-mail: marketingme@ferring.com
Website: www.ferringme.com

CS ELLA

TTPI

توسعه تجهیزات پزشکی ایرانیان

GI STENTS



- BD Stent — Biodegradable
- HV Stent Plus
- Flexella Plus
- Enterella — Pyloroduodenal
- Enterella — Colorectal
- Danis Seal
- Danis Stent
- Boubella
- Boubella-E
- Nitinella Plus

نمایندگی انحصاری استنت های گوارشی زیست تخریب پذیر ELLA در ایران

تهران، خیابان شهید بهشتی، نرسیده به
قائم مقام فراهـانی، پلاک ۴۰۲، واحد ۲۲
تلفن: ۸۸ ۳۱ ۷۸۵۰ - ۰۲۱
Web: www.ttpimed.com
E-mail: info@ttpimed.com

ELLA - CS

Rojan

SOVODAK

Daclatasvir / Sofosbuvir

60 mg / 400 mg

ONE PILL A DAY FOR ALL HCV GENOTYPES

درمان بسیار ساده هپاتیت C

روزانه یک قرص برای تمام ژنوتیپ ها

تحت پوشش بیمه درمانی

تایید شده توسط بزرگترین کارآزمایی بالینی

شرکت آرمان ایده گستر پارس
وارد کننده تجهیزات مصرفی گوارشی
نماینده رسمی کمپانی های

HALYARD HEALTH
M.I.Tech Co., Ltd.
VEDKANG MEDICAL
AGS MEDTECH



وارد کننده تخصصی محصولات گوارش و کبد و انواع تجهیزات اندوسکوپی

N·I·S
NikanTebSasan
Medical Equipment Importer
In the Field of Gastroenterology & Hepatology

echosens™

US endoscopy

MICRO-TECH

Mar Flow®
MEDICAL EQUIPMENT

NO.146 ,19 St. North Karegar Ave. Tehran
Tell:+98 21 88 33 63 16
Cell:+98 912 833 63 16
Fax:+98 21 88 00 41 01
www.ntsco.ir

NOVARTIS



Oncology Scientific Exchange

- The Oncology Scientific Exchange (OSE) platform is a virtual environment offering healthcare professionals direct access to Novartis medical educational programs.
- The platform is an easy to navigate virtual environment, providing user with an interactive and engaging educational experience.

Platform can be accessed at www.ose.novartis.com

How to register to the OSE Platform

Please follow the steps below to register to the OSE Platform:

1. Navigate in your browser to www.ose.novartis.com
2. Click the button to **Register Now** – this will take you to the platform's registration page
3. Fill out the information requested in the form and click **Submit**. You will be automatically logged into the platform
4. You will only need to register to the OSE Platform once
5. Once you have accessed the platform, you can register for this webcast event by following the below guidance from point 2 onward

How to register to an OSE event

Please follow the steps below to make sure you register to the event and add a reminder to your calendar:

1. Log into the platform by visiting www.ose.novartis.com and sign in with your login information (see above)
2. Once logged in, navigate to the **Disease Area Theater**
3. Select the 'Live/Upcoming' tab
4. Register for this event by clicking the **Register Here** button under the event title
5. Add a reminder to your calendar for easy access on the day of the event

We look forward to welcoming you to this interactive webcast. If you have any questions, please do not hesitate to contact us.

NOVARTIS
Novartis Pharma Services AG, Iran Branch
No.18, 5th Floor, Alvand St., Argentina Sq., Tehran, Iran
Po-Box: 1514938117
Phone: +98 21 8867 1343 Fax: +98 21 8867 1526

LCC code:
Medical code:

NTS

شرکت مهندسی پزشکی
نقش طاووس صبا

وارد کننده کلیه تجهیزات پزشکی و بیمارستانی
و لوازم مصرفی بخش آندوسکوپی

LUMATEC

CMI CHOYANG

دستگاه شستشوی تمام اتوماتیک و ضدعفونی کننده آندوسکوپ
برای برند های:
OLYMPUS, FUJINON, PENTAX

نرم افزار ثبت گزارشات آندوسکوپی
گاستروسکوپی، کولونوسکوپی
برونکوسکوپی، آندوسونوگرافی، ERCP

Alton
مصرفی آندوسکوپی

OLYMPUS
مجوز تامین و تعمیر قطعات
دستگاه های آندوسکوپی OLYMPUS
از اداره کل تجهیزات و ملزومات پزشکی

خیابان مطهری، بین مفتح و سهروردی، نبش خیابان علی اکبری
ساختمان نقش طاووس، پلاک ۱۳۳، طبقه ۴، واحد ۱۲

۸۸ ۵۴ ۴۴ ۴۱-۲ ۰۲۱ ۸۸ ۷۵ ۰۴ ۵۱

۰۲۱ ۸۸۷۵۰۴۵۲

www.naghshtavous.com

naghshtavous@gmail.com
armin.naghshtavous@gmail.com

SonoScape

HD

Air/Water pumps

Washing Machine

Capturing & Reporting

M
A
C
S



دکتر دکتر

نوبت‌دهی و مدیریت مطب پزشکان

کنترل مطب در دستان شماست

۴ سال تحقیق برای ارائه خدماتی **متناسب با نیاز شما.**

نشان ملی ثبت
(رسانه های دیجیتال)

نماد اعتماد الکترونیکی

انجمن صنفی کسب و کارهای اینترنتی

عضو اتحادیه کشوری
کسب و کارهای مجازی

drdr.ir

sale@drdr.ir

(۰۲۱) ۴۲۱ ۹۸۰۰۰

۰۹۲۰ ۴۲۱ ۹۸۰۰

/drdr.ir

/in/drdr-ir

FARHAM
فرآوران همگام
عرضه کننده تجهیزات و لوازم مصرفی پزشکی

NaturLifeStyle

Colon Hydrotherapy

سلامتی، به طور طبیعی زیباست

ویژگی مدل های Professional و Portable

- تنها دستگاه کولون هیدروتراپی دارای سه مدل بیمارستانی، پرتابل و خانگی در ایران
- ساخت کمپانی Natur Life Style ایتالیا و دارای استاندارد CE اروپا
- شستشو و پاکسازی کامل روده بزرگ (کولون) بدون درد، ناراحتی و عوارض جانبی
- آمادگی روده بزرگ جهت انجام کولونسکوپی در کمترین زمان ممکن
- کمک به درمان یبوست (Constipation) حاد و مزمن با پاکسازی باکتری‌های مضر
- کمک به درمان اسهال (Diarrhea) حاد و مزمن با تخلیه باکتری‌های مضر
- آمادگی روده بزرگ جهت انجام جراحی‌های ناحیه شکمی و کلورکتال
- بدون نیاز به مصرف داروهای ملین و شیمیایی جهت پاکسازی روده
- آمادگی روده بزرگ جهت انجام تصویربرداری‌های تشخیصی
- تسکین علائم در بیماران دچار سندروم روده تحریک پذیر (IBS)
- آماده‌سازی روده بزرگ جهت زایمان طبیعی
- قابل استفاده برای بیماران مبتلا به بی اختیاری دفع
- دارای ۲ سال گارانتی و ۱۰ سال خدمات پس از فروش

تهران، خیابان احمد قصیر (بخارست)
کوچه پژوهشگاه (دوم)، پلاک ۶، طبقه ۲، واحد ۶
☎ ۰۲۱-۸۶۰۳۰۰۴۳
۰۲۱-۸۶۰۳۰۰۵۳
۱۵۱۴۶۱۵۵۱۸
۰۲۱-۸۸۷۵۱۲۶۲
www.farham.com
info@farham.com

SAGENE

آزمایشگاه ژنتیک پزشکی ساژن

Single Gene

MSI

MMRscreen

BRCA+

Pillcheck

HerCaP

تهران، میدان آرژانتین، خیابان الوند
بن بست برمک، پلاک ۷، طبقه ۳

۰۲۱-۸۶۰۸۱۴۸۲ | ۰۲۱-۸۶۰۸۵۳۱۷

info@sagene.ir

SAGENE.IR

شرکت فنی مهندسی
تصویر پرداز رایان طب
تیـرداد

نرم افزار ثبت تصاویر و گزارشات آندوسکپی

Aria Endoscopy Reporter

نرم افزار تصویربرداری Full HD برای ثبت تصاویر آندوسکپی

دارای مجوز از شورای عالی انفورماتیک و مرکز رسانه های دیجیتال







Endoskopi Flushing Pump

پمپ شستشوی آندوسکپی دستگاه گوارش





۰۲۱-۴۶۰۹۱۶۰۷
آدرس : تهـران ، اتوبـان حکیـم ، شهر زیبا
بلوار تعاون، مجتمع تجاری اداری میلاد
طبقه هفتم ، واحد ۴۵